👋 Last week we welcomed Dr. Roberto Salgado to the BIG office to talk about his upcoming #SABCS25 presentation on BIG’s exploratory #APHINITY #TILs research. Stay tuned! Insights coming soon!

Yesterday at #BePrecise2025, @aftimosp highlighted #AURORA, an academic study led by @BIGxResearch & mainly supported by @BCRFCure. It identifies genetic changes in mBC—showcasing how molecular profiling drives #precisiononcology to guide treatment & improve outcomes @be__precise

Today, BIG’s team, Virginie Adam & Thayane Crestani, are at #BePrecise2025, where collaboration between clinicians & researchers highlights how #precisiononcology can enhance patient care: Cancer profiling, Targeted therapies, Multi-omics, AI & molecular imaging. @be__precise

🎉 The EXPERT trial has reached its recruitment target! Thanks to all the participants. This trial will be able to confirm if the Prosigna (PAM50) assay can identify women who may safely omit radiation therapy after breast cancer surgery. @BCTrialsANZ

New pub 📢 The #POSITIVEtrial manuscript led by @IDemeestere has been published in The Breast! It explores hormonal factors predictive of fertility in young women with #breastcancer interrupting #endocrinetherapy to try for pregnancy. @etop_ibcsg 🔗 www.thebreastonline.com/article/S096...

🙋‍♂️ How can we 📈 access to innovation for ALL patients with breast caner ❓ @bigxresearch.bsky.social commentary 📝👇 www.nature.com/articles/s41... 🙏 to co-authors✍️ Successes of the past ✅ Pitfalls of the present ✅ Solutions for the future eg OptimaYoung 👇

📢 New open-access article in npj Breast Cancer, co-authored by BIG’s leadership, explores the challenges of academic clinical trials and how to ensure their future impact. 📄 Read more: www.nature.com/articles/s41... #BIGAgainstBreastCancer #breastcancer #research

What an honor to join the Executive Board of @bigxresearch.bsky.social! As someone living w metastatic breast cancer & connected to many other patients, I’m excited to support research that reflects what truly matters to people dealing with this disease. 🔗 bigagainstbreastcancer.org/about-big/go...

Earlier this week, our team attended the first AI in Oncology conference in Paris, led by Prof. Fabrice André. A brilliant exchange on how AI is shaping cancer research and care. Thank you IHU PRISM for an inspiring first edition! #AIinOncology @PrismCenter

Our Scientific Advisor, Thayane Crestani, is attending the @EORTC Course on Clinical Trial Statistics for Non-Statisticians in Brussels, strengthening our team’s expertise to support better clinical research in breast cancer, from study design to data interpretation. 💡📊 📈

We are thrilled to announce a new collaboration with @paige_ai , leaders in AI-driven cancer digital pathology. Our partnership aims to combine BIG’s clinical trial expertise & data w Paige's AI capabilities to revolutionize #breastcancer research & care 🔗 bit.ly/4kzSsBd

🧬 BIG’s Scientific Director, Virginie Adam, spoke to RTBF about the results from #SERENA-6 presented at #ASCO25. A blood test to detect molecular recurrence + new treatment cut the risk of progression by 56%! 📖 Read more (in FR): www.rtbf.be/article/canc...

#SOFT&TEXT trials are the result of over 20 years of collaboration. Thank you to patients and their families, HC providers, study chairs and committees, collaborators, the cross-Atlantic groups & the funders. @etop_ibcsg @theNCI @BCRFcure #ASCO25

Happening NOW at #ASCO25 !! Poster presented by @GuiNaderMarta on long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the #ALTTOtrial ! Go check poster 135! @JulesBordet @DanaFarber @Harvard

Happening NOW at #ASCO25 !! Poster 119 presented by @KristinaFanucci on evaluation of treatment-related neutropenia as a predictor of response to adjuvant #palbociclib in the #PALLASTrial @ABCSGVienna @alliance_trials

TREAT ctDNA trial A BIG supporter study led by @EORTC compares #elacestrant vs. standard ET in ER+/HER2- BC pts with #ctDNA relapse. Enrollment is open in 12 countries and will involve 120 sites. Go check 210b TiP poster presented by @MIgnatiadis at #ASCO25. #bcsm

The voice of Early Career Investigators is heard at the #BIG-NCTN Annual Meetings, Drs @darioT_ and @io_zerdes are speaking on the need for #younginvestigators ' involvement and support in patient-centered #clinicalresearch. @theNCI @bcrfcure.bsky.social

#ASCO25: Assessment of #breastcancer Index benefit in #premenopausal pts receiving OFS-containing adjuvant #endocrinetherapy was compared btw #SOFT&TEXT cohorts and validation of the prognostic performance of BCI was conducted, go check Poster #150 @etop_ibcsg @oreganruth

Thank you to Dr. @BraunMDPhD for his great talk at the 2025 #BIG-NCTN Annual Meeting. Here, he explains how cancer vaccines work to treat cancer. @theNCI @BCRFcure @YaleCancer #ASCO25 #vaccines #breastcancer

Day 2 of the 2025 BIG-NCTN Annual Meeting in Chicago is ongoing to continue discussions on #breastcancer research and how joint efforts can be accomplished. @BCRFcure @theNCI

Day 1 of the BIG-NCTN Annual Meeting finishes with a dinner gathering all participants from both BIG and @theNCI networks and @BCRFcure leaders to celebrate the 20th Anniversary of the BIG_NCTN collaboration. @OncoAlert

New publication in the European Journal of Cancer: Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal pts with ER+ #breastcancer: A retrospective analysis of the #SOLE trial 🔗www.ejcancer.com/article/S0959-8049(25)00219-9/fulltext @OncologyAdvance

An abstract (e23009) has now been published at #ASCO25 on the BIG - Patient Partnership model for facilitating meaningful patient involvement in the design and conduct of cancer research, click here to read: meetings.asco.org/abstracts-pr...

#ESMObreast25 has come to a close with major insights from BIG studies. From long-term survival data to fertility and patient-reported outcomes, here are key takeaways from the event. #Aphinitytrial #Optimatrial #Positivetrial #ALTTOtrial #Pallastrial #ALPHABETtrial #BCSM

@TanjaSpanic at #ESMOBreast25 speaks about the importance of patients' involvement in #clinicalresearch @EORTC_QLG @EuropaDonnaEUR

Great to meeting you all in another day of #ESMOBreast25 Drs. Janice Tsang @aftimosp @BalicMarija @Carmela_surgery

Thank you to Dr. Janice Tsang for highlighting the importance of #survivorship in #breastcancer women, this very important to listen. #ESMOBreast25 #ESMO #BCSM

Thank you to Dr. Janice Tsang for highlighting the importance of #survivorship in #breastcancer women, this very important to listen. #ESMOBreast25 #ESMO #BCSM

#ESMOBreast25 Dr. Evangelia Razis, a BIG Executive Board member is talking about #LMD research in #breastcancer and mentioning the BIG Brain Metastasis task force and the BIG- #NCTN collaboration. @theNCI @BCRFcure

Although @JulesBordet and BIG office are in Brussels, and we have regular virtual meetings together, it's always nice to meet IJB colleagues at #ESMOBreast25 @ElisaAgostinett @ChiaraDauccia @Lucarecco @Carmela_surgery #MyESMO

It's an honor to meet with @AngelZotano, co- principal investigator of the #Aurora program at #ESMOBreast25. @Carmela_surgery #BCSM

Analysis of the BIG’s #ALTTO trial is presented by @riccardo_gerosa, reporting long-term outcomes of pts w/ HER2-positive #breastcancer and rare special histologies in the ALTTO Ttrial. Go check 226P.

Perez Fidal presenting an analysis from the #ALPHABETstudy on #PIK3CA mutational status concordance btw plasma and tumor in HER2 positive advanced #breastcancer #ESMO #BCSM @GEICAM #ESMOBreast25

#APHINITY: the final OS results support the use of #pertuzumab in eBC w/ clinically meaningful benefits for people with HER2+ disease. We thank the study participants, their families, recruiting physicians, study committees, FSS, @JulesBordet @LoiblSibylle #ESMOBreast25 #BCSM #ESMO

Dr Han Yi Lee was interviewed at #ESMOBreast25 on the results #328P of the BIG international physician survey on HER2 targeted therapy for mBC long-term survivors #BCSM

#ESMOBreast25 #328P BIG survey results from 237 physicians, 38 countries: 60% believe HER2+ MBC pts can be cured; 44% agree maintenance anti-HER2 can be stopped; but <25% of HER2+ MBC long-term survivors w/ no evidence of disease discontinued HER2 target therapy.

#APHINITY: IDFS benefit remains clinically meaningful in the N+ subgroup. No IDFS benefit observed in the N- subgroup. No new cardiac safety concerns emerged. @LoiblSibylle #ESMOBreast25 @JulesBordet @IEOufficiale FSS #BCSM #ESMO

#APHINITY: In this pre-specified OS analysis w/ longer follow-up, a statistically significant OS benefit was observed with the addition of #adjuvant #pertuzumab to #trastuzumab & chemo. @LoiblSibylle #ESMOBreast25 @JulesBordet @IEOufficiale #FSS #BCSM #ESMO

#ESMOBreast25: Preliminary results of the #OPTIMA BIG supporter trial were presented by Dr Rob Stein @uniofwarwick @UoLondon

Meet our BIG colleagues Drs. Carmela Caballero and Orsolya Birta at #ESMOBreast25, BIG is always happy to connect with #breastcancer community all around the world. @Carmela_surgery

#ESMOBreast25: Our scientific team, at the #PALLAStrial poster #307P reporting results of the relationship btw physician-graded symptomatic AEs and PROs #QualityofLife. @ABCSGVienna @alliance_trials

#ESMOBreast25 Don’t miss 117P presented by @PerezFidal on an analysis from the #ALPHABETstudy on #PIK3CA mutational status concordance btw plasma and tumor in HER2 positive advanced #breastcancer #ESMO #BCSM @GEICAM @CarmenCriscitiello @PhilBedard @MeredithRegan

Today at 12:00, #ESMOBreast25 poster session will open in Hall B0 and an analysis of the #PALLAStrial will be presented by Vesna Bjelic-Radisic at #307P, reporting the relationship btw physician-graded symptomatic AEs and pt-reported QoL. @ABCSGVienna @alliance_trials

Today at the #ESMOBreast25 poster session, an analysis of the BIG’s #ALTTO trial will be presented by @riccardo_gerosa, reporting long-term outcomes of pts w/ HER2-positive #breastcancer and rare special histologies in the ALTTO Ttrial. Go check 226P.

At #ESMOBreast25 mini oral session 1, @MariaCarmenDeS1 is reporting on a large and long-term analysis of post-mastectomy radiotherapy in HER2- positive #breastcancer patients of the BIG’s #ALTTO Trial! @serenadicosimo

Lower AMH at 3 mths was associated w/ lower pregnancy rate. Higher FSH at mth 3 was modestly associated w/ lower spontaneous pregnancy. Conclusion of the #POSITIVETrial is presented by @fedrophd at #ESMOBreast25 @etop_ibcsg @alliance_trials

NOW at #ESMOBreast25! A presentation by @fedrophd on predictive factors of #fertility in pts w/ #breastcancer interrupting #adjuvant #endocrinetherapy to attempt pregnancy in the #POSITIVE Trial @etop_ibcsg @alliance_trials

#APHINITY: The 1° analysis demonstrated IDFS benefit of adj #pertuzumab w/ #trastuzumab & chemotherapy. 3 previous Interim Analysis did not show OS benefit. The final OS analysis at 11.3 yrs median follow-up will be presented on 15 May at #ESMOBreast25 by @LoiblSibylle.

#APHINITY: LBA1 - The final overall survival analysis with a median follow-up 11.3 years will be presented at #ESMOBreast25 by @LoiblSibylle. Join us tomorrow at 15:00 in the Proffered Paper Session, room 14. @JulesBordet @IEOufficiale FSS

Learning about the latest advances in implementing #QoL tools in #clinicalresearch is key to improving trial development. Today, a member of our BIG scientific team is attending the @eortc.org #QoLConf25 in Barcelona to stay at the forefront of this important field.